PL359359A1 - Makrocykliczne inhibitory proteazy NS3-seryny wirusa zapalenia wątroby C, zawierające N-cykliczne reszty P2 - Google Patents

Makrocykliczne inhibitory proteazy NS3-seryny wirusa zapalenia wątroby C, zawierające N-cykliczne reszty P2

Info

Publication number
PL359359A1
PL359359A1 PL01359359A PL35935901A PL359359A1 PL 359359 A1 PL359359 A1 PL 359359A1 PL 01359359 A PL01359359 A PL 01359359A PL 35935901 A PL35935901 A PL 35935901A PL 359359 A1 PL359359 A1 PL 359359A1
Authority
PL
Poland
Prior art keywords
macrocyclic
hepatitis
moieties
virus
cyclic
Prior art date
Application number
PL01359359A
Other languages
English (en)
Inventor
Kevin X. Chen
Ashok Arasappan
Srikanth Venkatraman
Tejal N. Parekh
Haining Gu
F.George Njoroge
Viyyoor M. Girijavallabhan
Ashit Ganguly
Anil Saksena
Edwin Jao
Nanhua H. Yao
Andrew J. Prongay
Vincent S. Madison
Bancha Vibulbhan
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of PL359359A1 publication Critical patent/PL359359A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL01359359A 2000-04-05 2001-04-03 Makrocykliczne inhibitory proteazy NS3-seryny wirusa zapalenia wątroby C, zawierające N-cykliczne reszty P2 PL359359A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19460700P 2000-04-05 2000-04-05
PCT/US2001/010869 WO2001077113A2 (en) 2000-04-05 2001-04-03 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties

Publications (1)

Publication Number Publication Date
PL359359A1 true PL359359A1 (pl) 2004-08-23

Family

ID=22718227

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01359359A PL359359A1 (pl) 2000-04-05 2001-04-03 Makrocykliczne inhibitory proteazy NS3-seryny wirusa zapalenia wątroby C, zawierające N-cykliczne reszty P2

Country Status (26)

Country Link
US (1) US6846802B2 (pl)
EP (1) EP1268525B1 (pl)
JP (1) JP4748911B2 (pl)
KR (1) KR20030036152A (pl)
CN (1) CN1441806A (pl)
AR (1) AR029903A1 (pl)
AT (1) ATE419270T1 (pl)
AU (1) AU2001253124A1 (pl)
BR (1) BR0109861A (pl)
CA (1) CA2405521C (pl)
CZ (1) CZ20023321A3 (pl)
DE (1) DE60137207D1 (pl)
EC (1) ECSP014009A (pl)
ES (1) ES2317900T3 (pl)
HK (1) HK1047947A1 (pl)
HU (1) HUP0400456A3 (pl)
IL (1) IL151934A0 (pl)
MX (1) MXPA02009920A (pl)
NO (1) NO20024797L (pl)
NZ (1) NZ521455A (pl)
PE (1) PE20020188A1 (pl)
PL (1) PL359359A1 (pl)
RU (1) RU2002129564A (pl)
SK (1) SK14192002A3 (pl)
WO (1) WO2001077113A2 (pl)
ZA (1) ZA200207845B (pl)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2169880T3 (es) 1996-10-18 2002-07-16 Vertex Pharma Inhibidores de proteasas de serina, particularmente de la proteasa ns3 del virus de la hepatitis c.
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
EP2161254B1 (en) 2002-03-05 2014-08-13 Sumitomo Chemical Company, Limited Intermediate for preparing a biaryl compound
NZ561851A (en) * 2002-04-11 2009-05-31 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
DK1654261T3 (da) 2003-05-21 2008-01-14 Boehringer Ingelheim Int Hepatitis C-inhibitorforbindelser
DE602004025569D1 (de) 2003-06-18 2010-04-01 Tranzyme Pharma Inc Makrozyklische motilin rezeptorantagonisten
JP4527722B2 (ja) 2003-08-26 2010-08-18 シェーリング コーポレイション Ｃ型肝炎ウイルスの新規のペプチド模倣性ｎｓ３−セリンプロテアーゼインヒビター
AR045596A1 (es) 2003-09-05 2005-11-02 Vertex Pharma Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc
WO2005028501A1 (en) 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
KR20060085248A (ko) * 2003-09-26 2006-07-26 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ3 세린 프로테아제의마크로사이클릭 억제제
KR20060130027A (ko) 2003-10-10 2006-12-18 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제의억제제
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
JP2007532479A (ja) 2003-11-20 2007-11-15 シェーリング　コーポレイション Ｃ型肝炎ウイルスｎｓ３プロテアーゼの脱ペプチド化インヒビター
WO2005070955A1 (en) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
PL1713823T3 (pl) * 2004-01-30 2010-04-30 Medivir Ab Inhibitory proteazy serynowej NS-3 HCV
US7683033B2 (en) 2004-02-04 2010-03-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
SI1719773T1 (sl) 2004-02-24 2009-08-31 Japan Tobacco Inc Kondenzirane heterotetraciklične spojine in njihova uporaba kot inhibitorji polimeraze HCV
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
CN1946692A (zh) 2004-02-27 2007-04-11 先灵公司 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的3,4－(环戊基)－稠合的脯氨酸化合物
WO2005087721A2 (en) 2004-02-27 2005-09-22 Schering Corporation Compounds as inhibitors of hepatitis c virus ns3 serine protease
KR20060124725A (ko) 2004-02-27 2006-12-05 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ3 프로테아제의 억제제
PE20051150A1 (es) 2004-02-27 2006-01-16 Schering Corp Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
TW200529823A (en) 2004-02-27 2005-09-16 Schering Corp Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
CA2566610A1 (en) 2004-05-20 2005-12-01 Schering Corporation Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
JP2005350417A (ja) * 2004-06-11 2005-12-22 Dai Ichi Seiyaku Co Ltd 還元的エーテル化法を用いたピロリジン誘導体の製造法
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
ATE512971T1 (de) 2004-07-20 2011-07-15 Boehringer Ingelheim Int Peptidanaloga als hepatitis c-hemmer
WO2006026352A1 (en) 2004-08-27 2006-03-09 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2007001406A2 (en) * 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
JP4705164B2 (ja) * 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤
PE20070011A1 (es) * 2005-06-02 2007-03-08 Schering Corp Formulaciones farmaceuticas de compuestos inhibidores de proteasa del vhc o catepsina
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
AU2006276246B2 (en) 2005-07-25 2012-09-27 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis C virus replication
WO2007016441A1 (en) 2005-08-01 2007-02-08 Merck & Co., Inc. Macrocyclic peptides as hcv ns3 protease inhibitors
US20070105781A1 (en) * 2005-08-02 2007-05-10 Steve Lyons Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
SI2194043T1 (sl) * 2005-08-19 2014-04-30 Vertex Pharmaceuticals Incorporated Postopki
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
CN101415705B (zh) 2005-10-11 2011-10-26 因特蒙公司 抑制丙型肝炎病毒复制的化合物和方法
EP2392590A3 (en) 2005-11-11 2012-03-14 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2340836A1 (en) 2006-02-27 2011-07-06 Vertex Pharmceuticals Incorporated Co-crystals comprising VX-950 and their pharmaceutical compositions
CA2646229A1 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) * 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
BRPI0716060A2 (pt) 2006-08-17 2013-09-17 Boehringer Ingelheim Int inibidores de polimerase viral.
EP2079480B1 (en) 2006-10-24 2013-06-05 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
JP2010507656A (ja) 2006-10-24 2010-03-11 メルク エンド カムパニー インコーポレーテッド Ｈｃｖｎｓ３プロテアーゼ阻害剤
WO2008051475A2 (en) * 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
ES2444575T3 (es) * 2006-10-27 2014-02-25 Merck Sharp & Dohme Corp. Inhibidores de la proteasa NS3 del VHC
KR101615500B1 (ko) * 2006-10-27 2016-04-27 머크 샤프 앤드 돔 코포레이션 Ｈｃｖ ｎｓ3 프로테아제 억제제
JP2010513450A (ja) 2006-12-20 2010-04-30 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス性インドール
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
MX2009006880A (es) 2006-12-22 2009-07-03 Schering Corp Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
MX2009006878A (es) * 2006-12-22 2009-07-07 Schering Corp Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
WO2008136815A2 (en) 2006-12-22 2008-11-13 Schering Corporation 5, 6-ring annulated indole derivatives and use thereof
EP2134717A2 (en) 2007-02-27 2009-12-23 Vertex Pharmceuticals Incorporated Inhibitors of serine proteases
AR065498A1 (es) * 2007-02-27 2009-06-10 Vertex Pharma Co- critales de vx-950 (un inhibidor del virus de la hepatitis c) y composiciones farmaceuticas que los comprenden
BRPI0811020A2 (pt) * 2007-05-03 2015-07-21 Intermune Inc Composto, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática, de intensificação da função hepática em indivíduo com infecção do vírus da hepatite c e métodos de síntese de compostos, de administração de inibidor da infecção do vírus da hepatite c (hcv) e de distribuição de forma de dosagem oral.
CN101815533A (zh) 2007-05-04 2010-08-25 弗特克斯药品有限公司 用于治疗hcv感染的组合治疗
WO2008141227A1 (en) 2007-05-10 2008-11-20 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
EP2178885A1 (en) 2007-07-17 2010-04-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic indole derivatives for the treatment of hepatitis c infections
CN101754974B (zh) 2007-07-19 2016-02-03 Msd意大利有限公司 作为抗病毒剂的大环化合物
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
AR068107A1 (es) * 2007-08-29 2009-11-04 Schering Corp Derivados indolicos 2,3 sustituidos y una composicion farmaceutica
MX2010002318A (es) * 2007-08-29 2010-03-22 Schering Corp Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
EP2408761B1 (en) 2007-08-29 2014-01-01 Merck Sharp & Dohme Corp. Substituted indole derivatives and methods of use thereof
CA2704284A1 (en) 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
EP2219454A4 (en) 2007-11-14 2012-05-30 Enanta Pharm Inc HEMMER OF MACROCYCLIC TETRAZOLYL HEPATITIS C SERIN PROTEASE
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
MX2010005356A (es) * 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
JP5416708B2 (ja) * 2007-11-16 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション ３−アミノスルホニル置換インドール誘導体およびそれらの使用方法
WO2009079352A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Macrocyclic oximyl hepatitis c serine protease inhibitors
WO2009079353A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic hcv serine protease inhibitors
AU2008338273B2 (en) 2007-12-19 2014-10-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
KR100967989B1 (ko) * 2008-01-16 2010-07-07 연세대학교 산학협력단 구조변경이 가능한 전환형 휠체어
TW200936131A (en) * 2008-02-04 2009-09-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
WO2009108507A1 (en) 2008-02-25 2009-09-03 Merck & Co., Inc. Therapeutic compounds
CA2719008A1 (en) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
EP2282762A2 (en) * 2008-04-15 2011-02-16 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
WO2009134624A1 (en) 2008-04-28 2009-11-05 Merck & Co., Inc. Hcv ns3 protease inhibitors
MX2010013630A (es) * 2008-06-13 2010-12-21 Schering Corp Derivados triciclicos de indol y metodos de uso de los mismos.
RS53420B (en) 2008-07-22 2014-12-31 Msd Italia S.R.L. MACROCYCLIC COMPOUNDS OF HINOXALINE, WHICH IS AN INHIBITOR OF HCV NS3 PROTEASES WITH OTHER HCV AGENTS
US8697694B2 (en) 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR072940A1 (es) 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituidos con etinilo y su uso en el tratamiento de infecciones virales
AR072939A1 (es) 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituidas con etenilo y su uso en el tratamiento de infecciones virales
EP2326628A1 (en) 2008-08-20 2011-06-01 Schering Corporation Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
SG172848A1 (en) 2009-01-07 2011-08-29 Scynexis Inc Cyclosporine derivative for use in the treatment of hcv and hiv infection
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8193372B2 (en) 2009-03-04 2012-06-05 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole HCV polymerase inhibitors
JP2012523419A (ja) 2009-04-08 2012-10-04 イデニク プハルマセウティカルス，インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
US8936781B2 (en) * 2009-05-13 2015-01-20 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis C virus inhibitors
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
MY186633A (en) * 2009-06-11 2021-07-31 Abbvie Bahamas Ltd Heterocyclic compounds as inhibitors of hepatitis c virus (hcv)
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
US9695191B2 (en) * 2009-08-05 2017-07-04 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
US20110081315A1 (en) * 2009-09-28 2011-04-07 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
JP2013512246A (ja) 2009-11-25 2013-04-11 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
MY159958A (en) 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
EP2536410B1 (en) 2010-02-18 2015-09-23 Merck Sharp & Dohme Corp. Substituted pyrimidine derivatives and their use in treating viral infections
AU2011224698A1 (en) 2010-03-09 2012-11-01 Merck Sharp & Dohme Corp. Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
CA2805440A1 (en) 2010-07-26 2012-02-09 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
DK2618831T3 (en) 2010-09-21 2016-04-04 Enanta Pharm Inc Macrocyclic prolinafledte HCV serine protease inhibitors
EP2621279B1 (en) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
JP2014515023A (ja) 2011-04-13 2014-06-26 メルク・シャープ・アンド・ドーム・コーポレーション ２’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
US20140378416A1 (en) 2011-09-14 2014-12-25 Michael P. Dwyer Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP3028265A4 (en) 2013-08-02 2017-06-21 Stephen Hollis Displacement sensor
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015065817A1 (en) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
JP2015155430A (ja) * 2015-04-02 2015-08-27 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ コンホメーションを固定された、合成マクロ環化合物
JP2017160247A (ja) * 2017-05-10 2017-09-14 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ コンホメーションを固定された、合成マクロ環化合物
WO2019055657A1 (en) * 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University BAF COMPLEX MODULATION COMPOUNDS AND METHODS OF USE
EP3820460A1 (en) * 2018-07-12 2021-05-19 The Board of Trustees of the Leland Stanford Junior University Methods for reversing hiv latency using baf complex modulating compounds
CN113387842A (zh) * 2021-07-08 2021-09-14 成都泰和伟业生物科技有限公司 一种通过OTf胺化合成芳香伯胺的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004669A1 (en) 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
DE69024378T2 (de) 1989-02-01 1996-09-12 Asahi Glass Co Ltd Azeotrope oder azeotropähnliche Zusammensetzung auf der Basis von Chlorfluorkohlenwasserstoffen
IE911129A1 (en) 1990-04-04 1991-10-09 Chiron Corp Hepatitis c virus protease
ES2169880T3 (es) 1996-10-18 2002-07-16 Vertex Pharma Inhibidores de proteasas de serina, particularmente de la proteasa ns3 del virus de la hepatitis c.
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
ES2234144T3 (es) * 1997-08-11 2005-06-16 Boehringer Ingelheim (Canada) Ltd. Analogos de peptidos inhibidores de la hepatitis c.
GB9812523D0 (en) * 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6576613B1 (en) * 1998-07-24 2003-06-10 Corvas International, Inc. Title inhibitors of urokinase
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.

Also Published As

Publication number Publication date
HK1047947A1 (zh) 2003-03-14
BR0109861A (pt) 2003-06-10
CA2405521C (en) 2010-06-29
EP1268525A2 (en) 2003-01-02
SK14192002A3 (sk) 2003-03-04
HUP0400456A2 (hu) 2004-06-28
EP1268525B1 (en) 2008-12-31
NO20024797D0 (no) 2002-10-04
WO2001077113A3 (en) 2002-06-20
RU2002129564A (ru) 2004-05-10
HUP0400456A3 (en) 2005-09-28
US20020107181A1 (en) 2002-08-08
CA2405521A1 (en) 2001-10-18
IL151934A0 (en) 2003-04-10
KR20030036152A (ko) 2003-05-09
ES2317900T3 (es) 2009-05-01
PE20020188A1 (es) 2002-03-13
JP2003530401A (ja) 2003-10-14
US6846802B2 (en) 2005-01-25
MXPA02009920A (es) 2003-03-27
CZ20023321A3 (cs) 2003-01-15
NO20024797L (no) 2002-12-04
AU2001253124A1 (en) 2001-10-23
JP4748911B2 (ja) 2011-08-17
WO2001077113A2 (en) 2001-10-18
CN1441806A (zh) 2003-09-10
NZ521455A (en) 2004-06-25
ECSP014009A (es) 2003-03-31
ATE419270T1 (de) 2009-01-15
DE60137207D1 (de) 2009-02-12
AR029903A1 (es) 2003-07-23
ZA200207845B (en) 2004-02-11

Similar Documents

Publication Publication Date Title
IL151934A0 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
IL151935A0 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
AU2002230763A8 (en) Inhibitors of hepatitis c virus ns3 protease
AU2001245356A1 (en) Inhibitors of hepatitis c virus ns3 protease
HK1058047A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2055301A (en) Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
AU6371900A (en) Lactam inhibitors of hepatitis c virus ns3 protease
AU8063701A (en) Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
IL155842A0 (en) Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2002230764A1 (en) Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
AU2001280640A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2001277967A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
GB0107924D0 (en) Inhibitor of hepatitis C virus NS3 protease
HUP0000152A2 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
IL174459A0 (en) Macrocyclic inhibitors of hepatitis c virus ns3 serine protease
SI1169339T1 (en) Macrocyclic peptides inhibiting the hepatitis c virus ns3 protease
AU2001282922A1 (en) Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
GB9825946D0 (en) Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
SI0932617T1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
EP1141255A4 (en) MODIFIED FORMS OF HEPATITIS C VIRUS NS3 PROTEASE
AU2001269092A1 (en) Inhibitors of hepatitis b virus infection
AU2001254670A1 (en) Detection of hepatitis b virus rna
AU2002350322A1 (en) Inhibitors of hepatitis c virus protease
SI1326632T1 (sl) Proteasomski inhibitorji za zdravljenje infekcij s hepatitis virusi
AU2002308200A1 (en) Peptides and their use as inhibitors of hepatitis c virus ns3 protease

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)